enVVeno Medical Announces the Development of a Transcatheter Based Replacement Venous Valve for the Treatment of Chronic Venous Insufficiency

~ Potential relief to approximately 3.5 million CVI sufferers ~ Designed to be used by an expansive network of physicians ~ Initial bench testing and animal testing successfully completed ~ Awaiting regulatory approval to begin first-in-human testing, which is expected by end of 2022 ~ Company to host conference call with live audio webcast today, Wednesday, September 21st at 4:30 PM ET

Daniel Carlson

September 27, 2022

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.